These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9625129)

  • 1. Soluble CD44 and CD44v6 serum levels in patients with colorectal cancer are independent of tumor stage and tissue expression of CD44v6.
    Weg-Remers S; Hildebrandt U; Feifel G; Moser C; Zeitz M; Stallmach A
    Am J Gastroenterol; 1998 May; 93(5):790-4. PubMed ID: 9625129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma.
    Saito H; Tsujitani S; Katano K; Ikeguchi M; Maeta M; Kaibara N
    Cancer; 1998 Sep; 83(6):1094-101. PubMed ID: 9740073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer.
    Kawano T; Yanoma S; Nakamura Y; Shiono O; Kokatu T; Kubota A; Furukawa M; Tsukuda M
    Am J Otolaryngol; 2005; 26(5):308-13. PubMed ID: 16137528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble CD44v6 is not a sensitive tumor marker in patients with head and neck squamous cell cancer.
    Andratschke M; Chaubal S; Pauli C; Mack B; Hagedorn H; Wollenberg B
    Anticancer Res; 2005; 25(4):2821-6. PubMed ID: 16080532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer.
    Kopp R; Classen S; Wolf H; Gholam P; Possinger K; Wilmanns W
    Anticancer Res; 2001; 21(4B):2995-3000. PubMed ID: 11712800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
    Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
    Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of cytologic examination with ELISA assays for hyaluronan and soluble CD44v6 levels in evaluation of effusions.
    Afify A; Lynne LC; Howell L
    Diagn Cytopathol; 2007 Feb; 35(2):105-10. PubMed ID: 17230576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limitations of CD44v6 amplification for the detection of tumour cells in the blood of colorectal cancer patients.
    Masson D; Denis MG; Lustenberger P
    Br J Cancer; 2000 Apr; 82(7):1283-9. PubMed ID: 10755402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer.
    Kawano T; Yanoma S; Nakamura Y; Ozeki A; Kokatsu T; Kubota A; Furukawa M; Tsukuda M
    Acta Otolaryngol; 2005 Apr; 125(4):392-7. PubMed ID: 15823810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of CD44v6 has no prognostic value in patients with colorectal cancer.
    Jüngling B; Menges M; Goebel R; Wittig BM; Weg-Remers S; Pistorius G; Schilling M; Bauer M; König J; Zeitz M; Stallmach A
    Z Gastroenterol; 2002 Apr; 40(4):229-33. PubMed ID: 11961731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble CD44 variant 6 as a prognostic indicator in patients with colorectal cancer.
    Yamane N; Tsujitani S; Makino M; Maeta M; Kaibara N
    Oncology; 1999 Apr; 56(3):232-8. PubMed ID: 10202279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant 5 (sCD44-v5), and CD44 splice variant 6 (sCD44-v6) in patients with cervical cancer.
    Gadducci A; Ferdeghini M; Cosio S; Annicchiarico C; Fanucchi A; Prontera C; Bianchi R; Genazzani AR
    Anticancer Res; 1998; 18(1B):537-9. PubMed ID: 9568174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant v5 (sCD44-v5), and CD44 splice variant v6 (sCD44-v6) in patients with epithelial ovarian cancer.
    Gadducci A; Ferdeghini M; Fanucchi A; Annicchiarico C; Cosio S; Prontera C; Bianchi R; Genazzani AR
    Anticancer Res; 1997; 17(6D):4463-6. PubMed ID: 9494551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum soluble CD44v6 levels in patients with oral and maxillofacial malignancy.
    Chang SM; Xing RD; Zhang FM; Duan YQ
    Oral Dis; 2009 Nov; 15(8):570-2. PubMed ID: 19563418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of treatment outcome by CD44v6 after total mesorectal excision in locally advanced rectal cancer.
    Peng J; Lu JJ; Zhu J; Xu Y; Lu H; Lian P; Cai G; Cai S
    Cancer J; 2008; 14(1):54-61. PubMed ID: 18303484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical expression of bcl-2 in UICC stage I and III colorectal carcinoma patients: correlation with c-erbB-2, p53, ki-67, CD44, laminin and collagen IV in evaluating prognostic significance.
    Zavrides H; Zizi-Sermpetzoglou A; Elemenoglou I; Papatheofanis I; Peros G; Athanasas G; Panousopoulos D
    Pol J Pathol; 2006; 57(3):149-59. PubMed ID: 17219742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance.
    Nguyen VN; Mirejovský T; Melinová L; Mandys V
    Neoplasma; 2000; 47(6):400-8. PubMed ID: 11263866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic assessment of the prognostic impact of membranous CD44v6 protein expression in colorectal cancer.
    Zlobec I; Günthert U; Tornillo L; Iezzi G; Baumhoer D; Terracciano L; Lugli A
    Histopathology; 2009 Nov; 55(5):564-75. PubMed ID: 19912362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma.
    Van Hal NL; Van Dongen GA; Ten Brink CB; Heider KH; Rech-Weichselbraun I; Snow GB; Brakenhoff RH
    Clin Cancer Res; 1999 Nov; 5(11):3534-41. PubMed ID: 10589769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble CD44: quantification and molecular repartition in plasma of patients with colorectal cancer.
    Masson D; Denis MG; Denis M; Blanchard D; Loirat MJ; Cassagnau E; Lustenberger P
    Br J Cancer; 1999 Aug; 80(12):1995-2000. PubMed ID: 10471052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.